- Samsung Biologics placed in leadership band with A- grade

-三星生物制品以A级名列领导地位

- Leadership status recognition of implementing current best practices

-实施当前最佳实践的领导地位认可

INCHEON, South Korea, Feb. 13, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced that it has received the Leadership status and A- rating from the Carbon Disclosure Project (CDP).

韩国仁川，2024年2月13日，全球合同开发和制造组织（CDMO）三星生物制品（KRX:207940.KS）今天宣布，它已获得碳披露项目（CDP）的领导地位和a级评级。

The leadership rating is a recognition of the company's ongoing efforts to mitigate the risks of climate change and implementation of the current best practices. The CDP, a non-profit organization that annually evaluates corporate environmental transparency, disclosed over 23,000 companies worldwide across 17 categories, including governance, risk management processes, business strategy and opportunity disclosure.

领导力评级是对公司持续努力减轻气候变化风险和实施当前最佳实践的认可。CDP是一家每年评估公司环境透明度的非营利组织，它披露了全球17个类别的23000多家公司，包括治理、风险管理流程、业务战略和机会披露。

Samsung Biologics was granted Management status and B rating in 2022..

三星生物制品公司于2022年获得管理资格和B级评级。。

'The leadership status reflects our progress in sustainability management and collaborative efforts to decarbonize across the supply chain,' said John Rim, CEO and President of Samsung Biologics. 'We will continue our environmental stewardship as we implement better services and practices along with our clients and suppliers to mitigate climate risks and build a healthier future.'.

三星生物制品（Samsung Biologics）首席执行官兼总裁约翰·里姆（JohnRim）说，领导地位反映了我们在可持续发展管理方面取得的进展，以及在整个供应链中脱碳的合作努力随着我们与客户和供应商一起实施更好的服务和实践，我们将继续进行环境管理，以减轻气候风险，建设更健康的未来。”。

Samsung Biologics has been bolstering sustainable operations and accelerating the transition to renewable energy by utilizing low-carbon technologies, such as ultra-low NOx burners, solar panels, and energy monitoring systems. The company is also an active member of the Sustainable Markets Initiative and supports various global initiatives, including the United Nations Global Compact and RE100.

三星生物制品（Samsung Biologics）一直在利用低碳技术，如超低氮氧化物燃烧器、太阳能电池板和能源监测系统，支持可持续经营，并加速向可再生能源的过渡。该公司也是可持续市场倡议的积极成员，并支持各种全球倡议，包括联合国全球契约和RE100。

Last month, Samsung Biologics received the Platinum Sustainability Rating from EcoVadis, the highest rank given, for its sustainability performance..

上个月，三星生物制品（Samsung Biologics）因其可持续性表现获得了EcoVadis的白金可持续性评级，这是排名最高的。。

About Samsung Biologics Co., Ltd.

关于三星生物制品有限公司。

Samsung Biologics (KRX: 207940.KS) is a fully integrated, end-to-end CDMO service provider, offering seamless development and manufacturing solutions from cell line development to final aseptic fill/finish as well as laboratory testing support for the biopharmaceutical products we manufacture. Our state-of-the-art facilities are cGMP compliant with bioreactors ranging from small to large scales to serve varying client needs.

三星生物制品（KRX:207940.KS）是一家完全集成的端到端CDMO服务提供商，为我们制造的生物制药产品提供从细胞系开发到最终无菌填充/表面处理的无缝开发和制造解决方案，以及实验室测试支持。我们最先进的设施符合cGMP，生物反应器的规模从小到大不等，以满足不同的客户需求。

To maximize our operational efficiency and expand our capabilities in response to growing biomanufacturing demand, Samsung Biologics completed Bio Campus I with Plant 4, offering a combined 604KL total capacity, and launched Bio Campus II with the construction of Plant 5, which will be operational in April 2025 adding 180KL biomanufacturing capacity.

为了最大限度地提高我们的运营效率并扩大我们的能力，以应对不断增长的生物制造需求，三星生物制品公司完成了生物园区一期的4号工厂，总容量为604KL，并启动了生物园区二期的5号工厂建设，该工厂将于2025年4月投入运营，增加了180KL的生物制造能力。

Additionally, Samsung Biologics America enables the company to work in closer proximity to clients based in the U.S. and Europe. We continue to upgrade our capabilities to accommodate our clients by investing in technologies such as an antibody-drug conjugate (ADC) facility, a dedicated mRNA manufacturing facility, and additional aseptic filling capacity.

此外，三星生物制品美国公司使该公司能够更接近美国和欧洲的客户。我们通过投资抗体-药物偶联物（ADC）设施、专用mRNA制造设施和额外的无菌灌装能力等技术，继续升级我们的能力，以适应客户。

As a sustainable CDMO partner of choice, we are committed to on-time, in-full delivery of the products we manufacture with our flexible manufacturing solutions, operational excellence, and proven expertise..

作为可持续发展的CDMO首选合作伙伴，我们致力于通过灵活的制造解决方案、卓越的运营能力和久经考验的专业技能，按时、全面交付我们制造的产品。。

Samsung Biologics Media ContactClaire Kim, Head of Marketing Communications[email protected]

三星生物制品媒体联系人Claire Kim，营销传播主管[受电子邮件保护]

SOURCE Samsung Biologics

来源：三星生物制品